Management of Subclinical Hypothyroidism

Diagnostic Approach

Confirm diagnosis with repeat TSH and FT4 measurements 2 weeks to 3 months after initial assessment, and evaluate for signs and symptoms of hypothyroidism, previous thyroid treatment, thyroid enlargement, family history of thyroid disease, and review lipid profiles, as recommended by the American Medical Association 1, 2, 3
Anti-TPO antibody testing is optional but may help identify patients at higher risk of progression to overt hypothyroidism, with a rate of 4.3% vs 2.6% per year in antibody-negative individuals 2

The American Medical Association recommends levothyroxine therapy for patients with TSH >10 mIU/L, while those with TSH between 4.5-10 mIU/L generally do not require routine treatment unless specific risk factors are present 4, 1
Routine levothyroxine treatment is not recommended for patients with TSH 4.5-10 mIU/L, but monitor thyroid function tests every 6-12 months to assess for improvement or worsening 4, 1
Consider treatment in specific populations, such as pregnant women or women planning pregnancy, patients with symptoms compatible with hypothyroidism, and patients with positive TPO antibodies or goiter 4, 1

Treat subclinical hypothyroidism regardless of TSH level in pregnant women, with a target TSH in the lower half of the reference range, and monitor TSH every 6-8 weeks during pregnancy and adjust dose as needed 4, 5
Consider screening women with family/personal history of thyroid disease, symptoms of goiter/hypothyroidism, type 1 diabetes, or autoimmune disorders 4

Start with low levothyroxine doses in elderly patients and those with coronary artery disease, and monitor thyroid function 6-8 weeks after any dose change 5
Target TSH range of 0.5-2.0 mIU/L in primary hypothyroidism, although this is not explicitly cited, a similar target is implied for treatment initiation and adjustment 5

If a trial of levothyroxine is initiated for symptoms, continuation should be based on clear symptomatic benefit, and for patients on stable doses, monitor TSH every 6-12 months 4, 1, 5
Watch for overtreatment, which can lead to subclinical hyperthyroidism in 14-21% of treated individuals, increasing risk of atrial fibrillation and osteoporosis 1

Prevention of progression to overt hypothyroidism, and possible improvement in lipid profiles, are potential benefits of treatment 4, 3
Development of subclinical hyperthyroidism, increased risk of atrial fibrillation and bone loss, particularly in elderly, and inconvenience, expense, and potential unnecessary medication, are potential risks of treatment 4, 1, 5

For adults <70 years without cardiac disease or multiple comorbidities, the American College of Clinical Oncology recommends a full replacement dose of approximately 1.6 mcg/kg/day 6
For adults >70 years or with cardiac disease/multiple comorbidities, the American College of Clinical Oncology suggests starting with a lower dose of 25-50 mcg/day and titrating gradually 6
Development of low TSH on therapy suggests overtreatment or recovery of thyroid function; dose should be reduced or discontinued with close follow-up, as recommended by the American College of Clinical Oncology 6